[go: up one dir, main page]

WO2008003748A3 - Cd300lg polypeptides and their use in treating autoimmune diseases - Google Patents

Cd300lg polypeptides and their use in treating autoimmune diseases Download PDF

Info

Publication number
WO2008003748A3
WO2008003748A3 PCT/EP2007/056815 EP2007056815W WO2008003748A3 WO 2008003748 A3 WO2008003748 A3 WO 2008003748A3 EP 2007056815 W EP2007056815 W EP 2007056815W WO 2008003748 A3 WO2008003748 A3 WO 2008003748A3
Authority
WO
WIPO (PCT)
Prior art keywords
cd300lg
polypeptides
autoimmune diseases
treating autoimmune
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/056815
Other languages
French (fr)
Other versions
WO2008003748A2 (en
Inventor
Tatjana Albrektsen
Kresten Skak
Jan Fleckner
Katja Brandt
Rene Ruckert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of WO2008003748A2 publication Critical patent/WO2008003748A2/en
Publication of WO2008003748A3 publication Critical patent/WO2008003748A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relatates to novel CD300LG polypeptides, more specifically soluble forms thereof and provides use thereof and methods for preventing and/or treating diseases and/or disorders such as inflammatory diseases, including various inflammatory autoimmune disorders, allergic hypersensitivity, allograft rejection and/or syndromes associated with increased CD300LG-FL polypeptide function on dendritic cells.
PCT/EP2007/056815 2006-07-07 2007-07-05 Cd300lg polypeptides and their use in treating autoimmune diseases Ceased WO2008003748A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116778 2006-07-07
EP06116778.9 2006-07-07

Publications (2)

Publication Number Publication Date
WO2008003748A2 WO2008003748A2 (en) 2008-01-10
WO2008003748A3 true WO2008003748A3 (en) 2008-04-17

Family

ID=37027862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/056815 Ceased WO2008003748A2 (en) 2006-07-07 2007-07-05 Cd300lg polypeptides and their use in treating autoimmune diseases

Country Status (1)

Country Link
WO (1) WO2008003748A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101233073B1 (en) 2011-01-13 2013-02-14 강원대학교산학협력단 Pharmaceutical composition comprising peptide having inhibitory activities against transendothelial migration of leucocytes and metastasis of cancer cells
KR101291764B1 (en) 2011-03-04 2013-08-01 경북대학교 산학협력단 CD300a synthetic peptides and compositions for regulation of immune response comprising thereof
WO2017135277A1 (en) * 2016-02-03 2017-08-10 国立感染症研究所長が代表する日本国 Cultured transgenic cell allowing growth of norovirus, and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046281A2 (en) * 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2003080667A2 (en) * 2002-03-22 2003-10-02 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2005056597A1 (en) * 2003-12-09 2005-06-23 Riken IMMUNOGLOBULIN Fc RECEPTOR PROTEIN

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046281A2 (en) * 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2003080667A2 (en) * 2002-03-22 2003-10-02 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2005056597A1 (en) * 2003-12-09 2005-06-23 Riken IMMUNOGLOBULIN Fc RECEPTOR PROTEIN

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CARSON M J ET AL: "Differential expression of the triggering receptors expressed on myeloid cells (TREMs) family of receptors by CNS microglia and PE", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 96, no. suppl 1, March 2006 (2006-03-01), pages 37, XP009096349, ISSN: 0022-3042 *
CHUNG D-H ET AL: "CMRF-35-like-molecular-1, a novel mouse myeloid receptor, can inhibit osteoclast formation", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 171, 2003, pages 6541 - 6548, XP002997904, ISSN: 0022-1767 *
DATABASE Geneseq [online] 20 January 2003 (2003-01-20), "Human polypeptide SEQ ID NO 1170.", XP002470025, retrieved from EBI accession no. GSP:ABP69123 Database accession no. ABP69123 *
DATABASE Geneseq [online] 22 September 2005 (2005-09-22), "Cancer cell diagnosis method-related human protein - SEQ ID 386.", XP002409457, retrieved from EBI accession no. GSN:AEB14103 Database accession no. AEB14103 *
DATABASE Geneseq [online] 25 August 2005 (2005-08-25), "Human h-eIgR-L.", XP002409456, retrieved from EBI accession no. GSN:AEA49996 Database accession no. AEA49996 *
DATABASE Geneseq [online] 25 August 2005 (2005-08-25), "Human h-eIgR-Salpha.", XP002470023, retrieved from EBI accession no. GSP:AEA50000 Database accession no. AEA50000 *
DATABASE Geneseq [online] 25 August 2005 (2005-08-25), "Human h-eIgR-Sbeta.", XP002470024, retrieved from EBI accession no. GSP:AEA50002 Database accession no. AEA50002 *
DATABASE Geneseq [online] 29 July 2004 (2004-07-29), "Human genome derived single exon protein #682.", XP002409455, retrieved from EBI accession no. GSN:ABO54448 Database accession no. ABO54448 *
DATABASE Geneseq [online] 4 December 2003 (2003-12-04), "Human immune response associated protein IRAP-6 SEQ ID NO:6.", XP002470026, retrieved from EBI accession no. GSP:ADB36335 Database accession no. ADB36335 *
TAKATSU ET AL: "CD300 antigen like family member G: A novel Ig receptor like protein exclusively expressed on capillary endothelium", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 348, no. 1, 15 September 2006 (2006-09-15), pages 183 - 191, XP005593049, ISSN: 0006-291X *
UMEMOTO EIJI ET AL: "Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow.", THE JOURNAL OF EXPERIMENTAL MEDICINE 12 JUN 2006, vol. 203, no. 6, 12 June 2006 (2006-06-12), pages 1603 - 1614, XP002470021, ISSN: 0022-1007 *
VIERTLBOECK B C ET AL: "The chicken immunoregulatory receptor families SIRP, TREM, and CMRF35/CD300L", IMMUNOGENETICS 2006 GERMANY, vol. 58, no. 2-3, February 2006 (2006-02-01), pages 180 - 190, XP002470022, ISSN: 0093-7711 *

Also Published As

Publication number Publication date
WO2008003748A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2008076437A3 (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2007044534A3 (en) Vegf analogs and methods of use
WO2006122222A3 (en) Shape tunable plasmonic nanoparticles
WO2007120842A3 (en) Methods and compositions for targeting c-rel
WO2009100342A3 (en) Disease markers and uses thereof
WO2009007849A3 (en) Il-23 receptor antagonists and uses thereof
WO2007126439A3 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2009022156A3 (en) Peptides for desensibilization against allergens
WO2008011392A3 (en) Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
WO2004085475A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
WO2006113140A3 (en) Novel compounds useful for bradykinin b1 receptor antagonism
WO2008094254A3 (en) Methods and compositions for the treatment of cancer or other diseases
EP2185514A4 (en) Vinyl-aryl derivatives for inflammation and immune-related uses
EP2572734A3 (en) Cytokine-based fusion proteins for treatment of immune disorders
WO2007047468A3 (en) Immunomodulation using placental stem cells
WO2008039390A3 (en) Compositions and methods for chitosan enhanced immune response
WO2006130580A3 (en) Mutant il-10
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2007100643A3 (en) Methods of using antibodies against human il-22
WO2006132969A3 (en) Incorporation of non-naturally encoded amino acids into proteins
WO2008127355A3 (en) Chemorepulsion of cells
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2009023267A3 (en) Methods for modulating development and expansion of il-17 expressing cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07787106

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07787106

Country of ref document: EP

Kind code of ref document: A2